← Back to Search

ABC Block for Postoperative Pain

Phase 4
Waitlist Available
Led By Michael Manning, MD
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 hours post-extubation
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial

Summary

This trial will study how a type of pain block affects recovery after heart surgery. Subjects will receive either the block or a dummy block.

Who is the study for?
This trial is for adults aged 18-85 undergoing elective cardiac surgery via median sternotomy, with a BMI of 18-50 kg/m2. It's not suitable for those with severe lung disease, very weak heart function (LVEF <30%), certain pre/post-operative conditions, drug or alcohol abuse history, chronic opioid use, amide anesthetic allergy, or major psychiatric disorders.
What is being tested?
The study tests the effectiveness of ABC blocks in pain management after cardiac surgery. Participants will be randomly assigned to receive either a local anesthetic (bupivacaine plus liposomal bupivacaine) or a saline sham block to compare recovery outcomes.
What are the potential side effects?
Possible side effects may include discomfort at the injection site, allergic reactions to the anesthetics used in the ABC blocks such as itching or rash, and less commonly nerve damage which could cause weakness or numbness.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 hours post-extubation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 hours post-extubation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Tracheal Extubation
Secondary study objectives
Tracheal Extubation
ICU length of stay
Time from end of case to tracheal extubation
+5 more

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: ABC block with bupivacaine and liposomal bupivacaineActive Control1 Intervention
The study solution used in the active arm will comprise 20 mL of liposomal bupivacaine (266 mg) admixed with 40 mL of 0.25% bupivacaine HCl. The solution will be administered as bilateral parasternal blocks (40 mL) and bilateral epigastric rectus sheath blocks (20 mL).
Group II: ABC block with salinePlacebo Group1 Intervention
The study solution used in the active arm will comprise 60 mL of 0.9% saline. The solution will be administered as bilateral parasternal blocks (40 mL) and bilateral epigastric rectus sheath blocks (20 mL).

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,458 Previous Clinical Trials
2,969,399 Total Patients Enrolled
25 Trials studying Pain
8,854 Patients Enrolled for Pain
Michael Manning, MDPrincipal InvestigatorDuke University

Media Library

ABC block with bupivacaine and liposomal bupivacaine Clinical Trial Eligibility Overview. Trial Name: NCT05589363 — Phase 4
Pain Research Study Groups: ABC block with bupivacaine and liposomal bupivacaine, ABC block with saline
Pain Clinical Trial 2023: ABC block with bupivacaine and liposomal bupivacaine Highlights & Side Effects. Trial Name: NCT05589363 — Phase 4
ABC block with bupivacaine and liposomal bupivacaine 2023 Treatment Timeline for Medical Study. Trial Name: NCT05589363 — Phase 4
~33 spots leftby Jul 2025